Kang Norbert V, Sojitra Nilesh, Glumicic Sinisa, Vlok Jacobus A, O'Toole Greg, Hannan S Alam, Sabbagh Walid
Royal Free Hospital NHS Trust, London, United Kingdom; Selston Cosmetic Clinic, Nottinghamshire, United Kingdom; and Glumicic Medical Group, Zagreb, Croatia.
Plast Reconstr Surg Glob Open. 2018 Jan 12;6(1):e1623. doi: 10.1097/GOX.0000000000001623. eCollection 2018 Jan.
The Earfold system, a new treatment for the correction of prominent ears, consists of 3 components: the Earfold implant, the Earfold introducer, and the Prefold positioner.
This is an interim report based on an ongoing analysis of safety in a series of patients treated for prominent ears with the Earfold implant between February 2013 and September 2014. Safety was assessed based on adverse event reports and the need for implant revision; follow-up is ongoing.
Seven surgeons used 1,200 Earfold implants to treat 403 patients (ages, 7-70 years; 63% male); the time since the initial implant procedure now ranges from 30 to 48 months. To date, 145 patients (36%) have returned for a follow-up visit (mean, 7.7 months [range, 1-34 months]). Adverse events requiring intervention have affected 39 of 403 (9.7%) patients; these include implant revisions (n = 17 [4.2%], most often due to implant visibility), skin erosion over the implant (n = 15 [3.7%]), and infection (n = 7 [1.7%]). Bleeding, recurrence of prominence, hematoma, deformity, or adverse scarring did not occur.
This interim analysis has shown that Earfold prominent ear correction system is associated with relatively few adverse events that require intervention; a small number of patients experienced infection, implant extrusion, or implant visibility that required revision. Most adverse events were related to either patient selection or technical errors at implantation. It is expected that with continued use of Earfold by surgeons experienced in otoplasty, the adverse event incidence will decrease.
耳褶系统是一种用于矫正招风耳的新型治疗方法,由三个组件组成:耳褶植入物、耳褶导入器和预褶定位器。
这是一份中期报告,基于对2013年2月至2014年9月期间使用耳褶植入物治疗招风耳的一系列患者的安全性进行的持续分析。根据不良事件报告和植入物翻修需求评估安全性;随访仍在进行中。
7名外科医生使用了1200个耳褶植入物治疗403例患者(年龄7至70岁;63%为男性);自初次植入手术以来的时间目前为30至48个月。迄今为止,145例患者(36%)已返回进行随访(平均7.7个月[范围1至34个月])。需要干预的不良事件影响了403例患者中的39例(9.7%);这些包括植入物翻修(n = 17[4.2%],最常见的原因是植入物可见)、植入物上方皮肤糜烂(n = 15[3.7%])和感染(n = 7[1.7%])。未发生出血、突出复发、血肿、畸形或不良瘢痕形成。
这项中期分析表明,耳褶招风耳矫正系统相关的需要干预的不良事件相对较少;少数患者出现感染、植入物挤出或植入物可见需要翻修。大多数不良事件与患者选择或植入时的技术错误有关。预计随着经验丰富的耳整形外科医生持续使用耳褶系统,不良事件发生率将会降低。